| 📌 The essentials The FDA has approved the first generic versions of dapagliflozin (Farxiga) tablets, the first SGLT2 inhibitor to reach generic status in the United States. Multiple generic manufacturers received approval simultaneously. Available doses: 5 mg and 10 mg tablets. Generic approval covers: type 2 diabetes (glycemic control and cardiovascular risk reduction) and reduction of risk of hospitalization for heart failure in adults with type 2 diabetes and cardiovascular disease or multiple cardiovascular risk factors. The brand-name Farxiga retains additional approved indications (heart failure with preserved ejection fraction, chronic kidney disease) that the generics do not yet carry. Current approximate pricing: brand-name Farxiga runs $550 to $650 per month without insurance; generic dapagliflozin is running approximately $290 to $410 per month with discount coupons (GoodRx, SingleCare) as of April 2026. Confirm current pricing at GoodRx.com/dapagliflozin as prices will continue to change with market competition. Verify therapeutic equivalence: check the FDA Orange Book to confirm which manufacturers have received “AB” ratings, indicating interchangeability. |
|---|
If you have been prescribing or taking Farxiga (dapagliflozin) for any length of time, you already know the conversation that tends to come up at refill time: the price. Without insurance, a 30-day supply of brand-name Farxiga runs between $550 and $650 per month. For a medication that many patients need to take daily and indefinitely, that is a meaningful barrier. The FDA’s approval of the first generic versions of dapagliflozin tablets changes that equation.
Multiple generic manufacturers have received approval simultaneously, and while generic pricing is not always as low as patients hope immediately after launch, the competitive pressure that comes with multiple manufacturers is what ultimately drives costs down. This is how the generic drug system is supposed to work.
Dapagliflozin: More Than a Diabetes Drug
Dapagliflozin belongs to a class of medications called SGLT2 inhibitors, short for sodium-glucose cotransporter 2 inhibitors. The mechanism is straightforward: the kidneys normally filter glucose from the blood and then reabsorb almost all of it back into circulation. SGLT2 inhibitors block the transporter protein responsible for that reabsorption, so excess glucose gets excreted in the urine instead. Lower blood glucose, less cardiovascular strain, less kidney filtration burden.
What made dapagliflozin and its SGLT2 classmates remarkable, and what eventually transformed both cardiology and nephrology practice, was what came out of the cardiovascular outcomes trials that the FDA mandated for all new diabetes drugs after 2008. Researchers expected to show the drugs were not harmful. What they found instead was that they were actively protective: significantly reducing hospitalizations for heart failure and slowing kidney disease progression, even in patients without diabetes.
The DAPA-HF trial, published in the New England Journal of Medicine in 2019, showed dapagliflozin reduced a composite of worsening heart failure or cardiovascular death by 26% versus placebo in patients with heart failure with reduced ejection fraction, including patients who did not have type 2 diabetes. The DAPA-CKD trial showed it reduced risk of a sustained decline in kidney function, end-stage kidney disease, or death from kidney or cardiovascular causes by 39% in patients with chronic kidney disease, again including non-diabetic patients. These were not minor findings. They were class-redefining.
| The indications that dapagliflozin currently carries, and what the generic covers Dapagliflozin’s full FDA-approved indication list includes: type 2 diabetes in adults (glycemic control plus cardiovascular risk reduction); reduction of risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors; heart failure with reduced ejection fraction (regardless of diabetes status); heart failure with preserved ejection fraction; and chronic kidney disease in adults at risk of progression. The generic approval currently covers the type 2 diabetes and heart failure hospitalization risk reduction indications specifically. The additional heart failure and CKD indications remain on the brand label but are not yet part of the generic labeling. As the evidence base matures, generic labeling may expand to match. For the complete current list, the FDA prescribing information is the authoritative source. |
|---|
Why Generic Approval Matters More for This Drug Than Most
Type 2 diabetes affects more than 40 million Americans, with 90 to 95% of all diabetes cases falling into this category. It is a condition that disproportionately affects lower-income populations and communities of color, exactly the populations for whom a $600-per-month medication is least accessible.
Despite its strong evidence base, adoption of SGLT2 inhibitor therapy in clinical practice has remained well below what guidelines recommend, and cost is consistently cited as a primary barrier. A 2025 review in npj Metabolic Health and Disease noted this explicitly, pointing to cost and clinician familiarity as the two main obstacles to uptake of a drug class with clear guideline support for reducing cardiovascular and kidney disease burden.
Generic availability does not immediately solve the cost problem, but it starts the clock. With discount coupons through services like GoodRx or SingleCare, generic dapagliflozin is currently available in the range of $290 to $410 per month for a 30-day supply, compared to $550 to $650 for the brand. That is a meaningful improvement, though still not cheap. As more manufacturers enter the market over the coming months, prices should continue to fall.
Current approximate price landscape (30-day supply):
| Option | Without Insurance | With Discount Coupon |
|---|---|---|
| Brand-name Farxiga | $550 to $650/month | ~$288 (GoodRx) |
| Generic dapagliflozin | $400 to $500/month | $290 to $410 (GoodRx/SingleCare) |
| With commercial insurance | Varies by plan | Copay $0 to $75 typical |
| AZ&Me patient assistance | Potentially $0 | Eligibility required |
AZ&Me is AstraZeneca’s patient assistance program for brand-name Farxiga. Patients who meet income eligibility can receive free medication. Details at azandme.com. Generic dapagliflozin is not covered under this program. Pricing figures are approximate as of April 2026 and subject to change.
What “Therapeutic Equivalence” Actually Means
A common question when a generic is approved: is it really the same? The short answer is yes, with a specific technical meaning. The FDA requires generics to demonstrate bioequivalence: they must deliver the same active ingredient in the same form, at the same dose, producing the same blood levels over the same time frame as the brand. The inactive ingredients (fillers, binders, coatings) can differ, which occasionally matters for patients with specific allergies or sensitivities, but the therapeutic effect is required to be equivalent.
Generics approved under this standard receive an “AB” rating in the FDA’s Orange Book, the Approved Drug Products database, indicating they are interchangeable at the pharmacy level without requiring a new prescription. You can check the Orange Book at accessdata.fda.gov/scripts/cder/ob/ to confirm which manufacturers have received approval and their equivalence rating.
Safety: The Generic Carries the Same Label
Generic dapagliflozin carries the same prescribing information, contraindications, warnings, and precautions as brand-name Farxiga. These are worth knowing, particularly for patients or prescribers newer to this drug class.
Contraindications
- Known serious hypersensitivity to dapagliflozin or any excipient in the formulation
- eGFR below the threshold specified in the label for the relevant indication (review the current label for the specific eGFR cutoffs by indication)
Key warnings to discuss with patients
Diabetic ketoacidosis (DKA): Can occur even with near-normal blood glucose (euglycemic DKA), a well-documented and sometimes underrecognized risk. Patients should be counseled to hold dapagliflozin before surgery and to recognize DKA symptoms including nausea, vomiting, abdominal pain, fatigue, and difficulty breathing.
Volume depletion: The osmotic diuretic effect can cause dehydration and hypotension, particularly relevant in older patients or those on diuretics. Assess volume status before initiating in high-risk patients.
Urinary tract and genital infections: The glucosuria that makes SGLT2 inhibitors effective also creates a more hospitable environment for yeast and bacterial infections. Genital mycotic infections are common, particularly in women. Counsel patients to report symptoms and maintain good hygiene.
Fournier’s gangrene: A rare but serious necrotizing fasciitis of the genitalia has been reported across the SGLT2 class. Patients with symptoms including pain, tenderness, redness, or swelling in the genital or perineal area should seek immediate care.
Lower limb amputations: A risk signal first identified with canagliflozin. The signal for dapagliflozin is less clearly established but warrants monitoring in high-risk patients including those with peripheral arterial disease or diabetic neuropathy.
As the SGLT2 class StatPearls reference notes, despite the substantial clinical advantages of this drug class, therapy requires attention to safety considerations including volume depletion, genital infections, diabetic ketoacidosis, and potential lower extremity complications. These are established safety signals, not new or unexpected findings with the generic.
| A note on perioperative management SGLT2 inhibitors should generally be held before scheduled surgery due to the risk of euglycemic DKA. The recommended hold period varies by guideline. The ADA recommends holding for at least 3 to 4 days prior to major surgery. This is a counseling point worth building into any practice that prescribes dapagliflozin, especially now that more patients may receive it via generic without a specialist involved in initiation. |
|---|
The Bigger Picture: Where This Drug Class Is Heading
Generic dapagliflozin’s arrival coincides with a remarkable moment for this drug class. SGLT2 inhibitors, initially developed as diabetes drugs, have become foundational therapies in cardiology and nephrology, a transformation that has happened faster than almost any comparable pharmacological shift in recent memory.
The 2024 to 2025 research cycle extended the evidence base further, with large meta-analyses showing benefits in acute myocardial infarction, acute decompensated heart failure, and non-diabetic chronic kidney disease without albuminuria. Trials are now exploring effects on cognitive decline, atrial fibrillation, and liver disease. Next-generation SGLT2-based compounds and dual SGLT1/SGLT2 inhibitors are in Phase II development.
There is also the Medicare context. Dapagliflozin and empagliflozin were selected as two of the first drugs for price negotiation under the Inflation Reduction Act, with negotiated prices taking effect in 2026. Generic competition and Medicare negotiation happening simultaneously represent an unusual convergence of affordability pressure on a single drug class. If that convergence translates to real-world access, it could meaningfully reduce the burden of undertreated cardiovascular and kidney disease in the populations that carry the highest risk.
For related coverage on how access to GLP-1 medications is being broadened through higher-dose approvals, see our post on Wegovy HD and the STEP UP trial data. For a parallel access story in diabetes care, our post on GLP-1 medications and PCOS covers how prescribing patterns in metabolic disease are shifting rapidly beyond original approved indications.
What to Watch Going Forward
Supply and availability
As of early 2026, generic manufacturers are still ramping up to full production capacity, which means spotty availability at some pharmacies, particularly in smaller markets. Calling ahead before a patient makes a trip to the pharmacy is practical advice worth passing along. Drug availability search tools like Medfinder can also help patients locate stock in real time.
Insurance formulary adjustments
Generic approval often triggers formulary changes. Some insurance plans may shift from covering brand-name Farxiga to preferring the generic, or may adjust tier placement. Patients on Farxiga who are told their insurance no longer covers it or covers it differently should check their updated formulary rather than assume the drug is not covered at all. Generic dapagliflozin should be therapeutically equivalent and typically at lower cost.
Expanding indications for the generic
The current generic approval covers type 2 diabetes and heart failure hospitalization risk reduction. As the evidence base continues to mature for heart failure with preserved ejection fraction and chronic kidney disease, it is worth watching whether FDA labeling for generic dapagliflozin expands to match the brand’s full approved indications.
Sources
FDA announcement: FDA Approves First Generic Dapagliflozin Tablets. FDA.gov.
Farxiga original FDA approval (T2D/CV): FDA approves dapagliflozin to reduce risk of hospitalization for heart failure in adults. FDA.gov.
Farxiga full prescribing information: Dapagliflozin prescribing information. accessdata.fda.gov.
Orange Book: FDA Approved Drug Products with Therapeutic Equivalence Evaluations. accessdata.fda.gov.
FDA generic drug bioequivalence: Generic Drug Facts. FDA.gov.
DAPA-HF trial: McMurray JJV et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381:1995-2008.
DAPA-CKD trial: Heerspink HJL et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383:1436-1446.
SGLT2 inhibitor class reference: Padda IS et al. Sodium-Glucose Transport 2 (SGLT2) Inhibitors. StatPearls. Updated September 2025.
Next-generation SGLT2 compounds: Cohen TD et al. Next-Generation SGLT2 Inhibitors: Innovations and Clinical Perspectives. Biomedicines. 2026;14(1):81.
Access barriers review: SGLT2 inhibitors across various patient populations in the era of precision medicine. npj Metabolic Health and Disease. 2025.
Inflation Reduction Act Medicare negotiation: Medicare Drug Price Negotiation. CMS.gov.
FDA cardiovascular outcomes trial guidance: Guidance for Industry: Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies. FDA.gov.
Fournier’s gangrene safety communication: FDA Drug Safety Communication: Rare but serious infection of the genitals and area around them. FDA.gov.
ADA perioperative guidance: Diabetes Care in the Hospital. ADA Standards of Care 2023.
Pricing tools: GoodRx: dapagliflozin | SingleCare: dapagliflozin
Patient assistance: AstraZeneca AZ&Me Program. azandme.com.
CDC type 2 diabetes: Type 2 Diabetes. CDC.gov.
| Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Drug pricing information reflects approximate figures at time of publication and is subject to change. Always consult a qualified healthcare provider or pharmacist regarding medication decisions, including decisions about switching from a brand-name product to its generic equivalent. |
|---|
Leave a Reply